Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its annual forecast on robust sales of its medical devices, including glucose-monitoring products. Sales of Abbott's medical devices have been strengthened in recent quarters due to a resurgence in the demand for joint replacements as well as other surgeries delayed during the COVID-19 pandemic. Industry bellwether and rival Johnson & Johnson said on Tuesday it continues to expect... Read this story